Abstract: An embodiment provides an imaging lens comprising first to third lens groups arranged sequentially from an object side to an image side and having refractive power, wherein the distances of the second lens group and the third lens group from the first lens group are variable such that a tele mode having a narrow angle of view and a wide mode having a wide angle of view can be implemented, the EFL in the tele mode is no more than 2.5 times the EFL in the wide mode, 2<Fnumber<5 and 15 mm<TTL?40 mm.

Abstract: The present invention provides a pharmaceutical composition or a food composition comprising, as active ingredients, flavone-6-C-glucose derivatives or galenical extracts containing flavone-6-C-glucose derivatives. The composition of the present invention shows a functional effect of effectively treating or preventing cognitive dysfunction disorders such as delirium, dementia or amnesia, stroke, palsy, attention disorders, anxiety disorders or sleep disorders.

Abstract: The present invention relates to an imaging lens and the present invention comprises: a first lens having a positive (+) refractive power; a second lens having a negative (?) refractive power; an iris (aperture); a third lens having a negative (?) refractive power; a fourth lens having a negative (?) refractive power; and a fifth lens having a positive (+) refractive power or negative (?) refractive power, wherein the first lens, the second lens, the third lens, the fourth lens and the fifth lens can be sequentially arranged along an optical axis from a subject side. Since the length of an optical system is shorter than a focal distance, the present invention can be effectively used for an imaging lens of an optical system requiring a low telephoto ratio.

Abstract: The present invention relates to the obesity-curative or obesity-preventive effect of a Polygonum cuspidatum butanol fraction and a Polygonum cuspidatum ethylacetate fraction, and more particularly, to a pharmaceutical composition and a functional food for treating obesity, the pharmaceutical composition and the functional food comprising a Polygonum cuspidatum butanol fraction (POCU-1b) and an ethylacetate fraction as active ingredients, wherein the Polygonum cuspidatum butanol fraction and the ethylacetate fraction inhibit effectively the activity of pancreatic lipase, an important enzyme involving in fat absorption in a living body, and have excellent inhibitory effect on fat absorption in the short term fat absorption-inhibitory animal experiments using lipid emulsions.

Abstract: The present invention provides a pharmaceutical composition or a food composition comprising, as active ingredients, flavone-6-C-glucose derivatives or galenical extracts containing flavone-6-C-glucose derivatives. The composition of the present invention shows a functional effect of effectively treating or preventing cognitive dysfunction disorders such as delirium, dementia or amnesia, stroke, palsy, attention disorders, anxiety disorders or sleep disorders.

Abstract: A method for testing an organic pattern including: forming an organic pattern on a test substrate through a mask; acquiring a test image by photographing a predetermined test area of the test substrate; and checking whether an edge of the organic pattern displayed to the test image goes over an edge of a virtual test figure.

Abstract: A method for testing an organic pattern including: forming an organic pattern on a test substrate through a mask; acquiring a test image by photographing a predetermined test area of the test substrate; and checking whether an edge of the organic pattern displayed to the test image goes over an edge of a virtual test figure.

Abstract: The present invention relates to a treatment agent for diabetic complications, and a method for the treatment of diabetic complications using the same. The present invention confirmed that Osteomeles schwerinae extract and its fractions inhibited the generation of AGEs, the index for diabetic complications, inhibited the activation of aldose reductase, had anti-cataract activity, and had anti-oxidative activity. Thus, the present invention relates to a preventive and therapeutic agent for diabetic complications containing the said Osteomeles schwerinae extract and its fraction as an active ingredient.

Abstract: A mask assembly includes a mask frame, the mask frame having an opening and a frame surrounding the opening, a pattern mask on the mask frame, the pattern mask including a pattern portion having at least one pattern overlapping the opening and a welding portion attached to the frame, and at least one support bar crossing the opening and attached to the pattern mask.

Abstract: The present invention relates to the obesity-curative or obesity-preventive effect of a Polygonum cuspidatum butanol fraction and a Polygonum cuspidatum ethylacetate fraction, and more particularly, to a pharmaceutical composition and a functional food for treating obesity, the pharmaceutical composition and the functional food comprising a Polygonum cuspidatum butanol fraction (POCU-1b) and an ethylacetate fraction as active ingredients, wherein the Polygonum cuspidatum butanol fraction and the ethylacetate fraction inhibit effectively the activity of pancreatic lipase, an important enzyme involving in fat absorption in a living body, and have excellent inhibitory effect on fat absorption in the short term fat absorption-inhibitory animal experiments using lipid emulsions.

Abstract: The present invention relates to a treatment agent for diabetic complications, and a method for the treatment of diabetic complications using the same. The present invention confirmed that Osteomeles schwerinae extract and its fractions inhibited the generation of AGEs, the index for diabetic complications, inhibited the activation of aldose reductase, had anti-cataract activity, and had anti-oxidative activity. Thus, the present invention relates to a preventive and therapeutic agent for diabetic complications containing the said Osteomeles schwerinae extract and its fraction as an active ingredient.

Abstract: A mask assembly includes a mask frame, the mask frame having an opening and a frame surrounding the opening, a pattern mask on the mask frame, the pattern mask including a pattern portion having at least one pattern overlapping the opening and a welding portion attached to the frame, and at least one support bar crossing the opening and attached to the pattern mask.

Abstract: The present invention related to method for the mass separation of magnolol from Magnoliae cortex or Magnoliae radix. The method comprises the steps of: 1) crushing Magnoliae cortex or Magnoliae radix, extracting the crushed material with organic solvent, adding n-hexane to the extract so as to obtain a n-hexane layer; 2) concentrating the n-hexane layer in a water bath at a temperature of 30-40° C. and a revolution speed of 40-200 RPM under reduced pressure so as to form a crude crystal; and 3) removing the n-hexane from the crude crystal, completely dissolving the crude crystal in chloroform, adding n-hexane to the n-hexane-containing solution, and leaving the solution to stand at room temperature so as to recrystallize the solution. In the method, a column chromatography step which is necessarily carried out in the general separation process is omitted so that separation process steps are reduced, leading to a saving in separation time.

Abstract: The present invention related to method for the mass separation of magnolol from Magnoliae cortex or Magnoliae radix. The method comprises the steps of: 1) crushing Magnoliae cortex or Magnoliae radix, extracting the crushed material with organic solvent, adding n-hexane to the extract so as to obtain a n-hexane layer; 2) concentrating the n-hexane layer in a water bath at a temperature of 30-40 ° C. and a revolution speed of 40-200 RPM under reduced pressure so as to form a crude crystal; and 3) removing the n-hexane from the crude crystal, completely dissolving the crude crystal in chloroform, adding n-hexane to the n-hexane-containing solution, and leaving the solution to stand at room temperature so as to recrystallize the solution. In the method, a column chromatography step which is necessarily carried out in the general separation process is omitted so that separation process steps are reduced, leading to a saving in separation time.